Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is...
First - waiting till it fills the gap @ 0.98
Then setting stop-loss @ 0.75
Then waiting for the results of their clinical studies.
Shall we see $2-3? Or $6-7 like from the forecasts of 2017-2018? Time will show.
Mind the fundamentals and news.
